VICTORIA, British Columbia, April 24, 2025 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology designed to optimize…
Eupraxia continues to observe positive treatment outcomes in its ongoing Phase 1b/2a trial, including for the first time clinical responses measured 9 months after dosing with EP-104GI At 9 months…
Data from Phase 1b/2a RESOLVE suggests EP-104GI has significant potential to improve the standard of care for patients with Eosinophilic Esophagitis (EoE) Cash runway to fund operations out to third…
VICTORIA, British Columbia, May 07, 2025 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology designed to optimize…
Eupraxia is a clinical-stage biotechnology company developing targeted therapies that leverage a proprietary extended-release delivery system to provide the right dose of a drug in the right place for the right amount of time.
Victoria office:
Eupraxia Pharmaceuticals
201-2067 Cadboro Bay Rd.
Victoria BC, V8R 5G4
Canada
Vancouver lab & office:
Eupraxia Pharmaceuticals
2198 Yukon St,
Vancouver, BC, V5Y 1L1
Canada